Elan Corp. (NYSE: ELN)
ELN operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. ELN was upgraded by analysts at Deutsche Bank from a “hold” rating to a “buy” rating last week. ELN has a 1 year target price estimate of 14.25.
Snapshot:
- Dec. 16 Close: $11.82
- Day’s Range: 11.57 – 11.94
- Volume: 3,224,220
- Avg. Vol. (3m): 2,617,180
- Market Cap: $6.95B
- EPS (ttm): 1.09
- P/E (ttm): 10.85
ITC Holdings Corp. (NYSE: ITC)
ITC Holdings Corp., through its subsidiaries, engages ...
Continue Reading →DEC